Published in N Engl J Med on August 01, 1996
Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate (2010) 2.40
Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening. J Urol (2014) 2.32
Age-specific reference ranges for serum PSA. N Engl J Med (1996) 1.61
Prostate cancers in men with low PSA levels--must we find them? N Engl J Med (2004) 1.52
Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold. Urology (2014) 1.43
Novel diagnostic biomarkers for prostate cancer. J Cancer (2010) 1.36
Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice. Prostate Int (2014) 1.09
Racial differences in the androgen/androgen receptor pathway in prostate cancer. J Natl Med Assoc (1999) 1.00
Prostate-specific antigen: any successor in sight? Rev Urol (2013) 0.95
The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate (2011) 0.95
The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0-10.0 ng/mL) in Nigeria. Arab J Urol (2012) 0.95
Racial and ethnic variation of PSA in global population: Age specific reference intervals for serum prostate specific antigen in healthy South Indian males. Indian J Clin Biochem (2004) 0.94
Five-year downstream outcomes following prostate-specific antigen screening in older men. JAMA Intern Med (2013) 0.93
Age-specific prostate specific antigen cutoffs for guiding biopsy decision in Chinese population. PLoS One (2013) 0.92
Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract (2002) 0.92
The Distribution of PSA Age-Specific Profiles in Healthy Irish Men between 20 and 70. ISRN Oncol (2012) 0.92
PSA screening: a view from the front lines. North York General-Branson Practice-Based Small Group. CMAJ (2000) 0.91
Prostate-specific antigen and androgens in African-American and white normal subjects and prostate cancer patients. J Natl Med Assoc (2000) 0.91
Region 2 of 8q24 is associated with the risk of aggressive prostate cancer in Caribbean men of African descent from Guadeloupe (French West Indies). Asian J Androl (2015) 0.90
Use of prostate-specific antigen in black men: age-adjusted reference ranges for maximal cancer detection. J Natl Med Assoc (1998) 0.88
Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values. J Natl Compr Canc Netw (2010) 0.84
Identification of genetic risk associated with prostate cancer using ancestry informative markers. Prostate Cancer Prostatic Dis (2012) 0.84
The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study. Asian J Androl (2016) 0.83
A hospital based study on reference range of serum prostate specific antigen levels. Indian J Med Res (2014) 0.82
Prostate cancer: epidemiology and screening. Rev Urol (2000) 0.81
Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? Urology (2007) 0.81
Racial disparities in prostate cancer incidence rates by census division in the United States, 1999-2008. Prostate (2015) 0.80
Associations of plasma concentrations of dichlorodiphenyldichloroethylene and polychlorinated biphenyls with prostate cancer: a case-control study in Guadeloupe (French West Indies). Environ Health Perspect (2014) 0.80
Age-specific reference ranges of serum prostate-specific antigen in Iraqi men. Arab J Urol (2011) 0.78
Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate. Indian J Clin Biochem (2006) 0.78
Prostate cancer outcome in Burkina Faso. Infect Agent Cancer (2011) 0.78
Copy number variation of GSTT1 and GSTM1 and the risk of prostate cancer in a Caribbean population of African descent. PLoS One (2014) 0.77
Biomarkers for prostate cancer: present challenges and future opportunities. Future Sci OA (2015) 0.77
Best screening tests for prostate cancer. West J Med (1998) 0.77
Prostate cancer: active surveillance in African American men. Nat Rev Urol (2013) 0.76
Immunoseroproteomic Profiling in African American Men with Prostate Cancer: Evidence for an Autoantibody Response to Glycolysis and Plasminogen-Associated Proteins. Mol Cell Proteomics (2016) 0.76
Prostate-specific antigen in black men. N Engl J Med (1997) 0.75
Allelic variability in PSA & AR genes: a novel biomarker on the horizon for carcinoma prostate. Indian J Med Res (2014) 0.75
The importance of screening African Americans for prostate cancer. J Natl Med Assoc (1997) 0.75
Prostate-specific antigen in black men. N Engl J Med (1997) 0.75
Prostate-specific antigen, sexual behavior, and sexually transmitted infections in US men 40-59 years old, 2001-2004: a cross-sectional study. Infect Agent Cancer (2007) 0.75
Polymorphisms of Estrogen Metabolism-Related Genes and Prostate Cancer Risk in Two Populations of African Ancestry. PLoS One (2016) 0.75
Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers. Postgrad Med J (2002) 0.75
Prostate-specific antigen in black men. N Engl J Med (1997) 0.75
Reference Ranges of Age-Related Prostate-Specific Antigen in Men without Cancer from Beijing Area. Iran J Public Health (2013) 0.75
Prostate-specific antigen in black men. N Engl J Med (1997) 0.75
Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer-Results from the SEARCH database. Cancer Epidemiol (2015) 0.75
Socioeconomic determinants of prostate-specific antigen testing and estimation of the prevalence of undiagnosed prostate cancer in an elderly Polish population based on the PolSenior study. Arch Med Sci (2016) 0.75
Preventing Unnecessary Invasive Cancer-Diagnostic Tests: Changing the Cut-off Points. Iran J Public Health (2012) 0.75
Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System. World J Urol (2016) 0.75
African-Americans, Hispanic Americans, and non-Hispanic whites without GERD or reflux symptoms have equivalent 24-h pH esophageal acid exposure. Dig Dis Sci (2013) 0.75
Phylogenetic species recognition and species concepts in fungi. Fungal Genet Biol (2000) 7.71
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med (1989) 7.01
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med (1998) 6.84
Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA (1993) 5.77
Hospital characteristics and mortality rates. N Engl J Med (1989) 4.97
Population-based study of survival after osteoporotic fractures. Am J Epidemiol (1993) 4.71
Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation (1998) 4.63
Racial and community factors influencing coronary artery bypass graft surgery rates for all 1986 Medicare patients. JAMA (1992) 4.36
The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol (1993) 3.66
Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med (2011) 3.63
Natural history of prostatism: risk factors for acute urinary retention. J Urol (1997) 3.59
Comparison of self-reported and medical record health care utilization measures. J Clin Epidemiol (1996) 3.47
Biased tests of association: comparisons of allele frequencies when departing from Hardy-Weinberg proportions. Am J Epidemiol (1999) 3.41
Incidence of reading disability in a population-based birth cohort, 1976-1982, Rochester, Minn. Mayo Clin Proc (2001) 3.18
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene (2008) 2.94
Software for optimal matching in observational studies. Epidemiology (1996) 2.84
The genetics of hyphal fusion and vegetative incompatibility in filamentous ascomycete fungi. Annu Rev Genet (2000) 2.77
The impact of requiring patient authorization for use of data in medical records research. J Fam Pract (1998) 2.64
Interpreting results of prostate-specific antigen testing for early detection of prostate cancer. J Gen Intern Med (1996) 2.57
A population-based study of school scoliosis screening. JAMA (1999) 2.54
Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med (1999) 2.54
Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol (1996) 2.48
Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis (2007) 2.46
Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer (1994) 2.43
Sex differences in evaluation and outcome of unstable angina. JAMA (2000) 2.33
Geographic variation of inflammatory bowel disease within the United States. Gastroenterology (1991) 2.33
ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis (2010) 2.24
Potential influence of migration bias in birth cohort studies. Mayo Clin Proc (1998) 2.19
PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci U S A (2000) 2.17
Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA (1995) 2.14
Desmoplastic malignant melanoma. J Am Acad Dermatol (1995) 2.08
The development of erectile dysfunction in men treated for prostate cancer. J Urol (2001) 1.97
Maternal recall of distant pregnancy events. J Clin Epidemiol (1998) 1.92
Twin studies of immunogenicity--determining the genetic contribution to vaccine failure. Vaccine (2001) 1.88
Inappropriate surgery for testicular cancer. Br J Hosp Med (1992) 1.84
Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol (1995) 1.82
Body fat distribution and male/female differences in lipids and lipoproteins. Circulation (1990) 1.79
Hip fracture incidence among elderly Asian-American populations. Am J Epidemiol (1997) 1.78
Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol (1996) 1.77
Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine (2001) 1.77
Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol (1995) 1.75
Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int J Cancer (2001) 1.74
Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med (1988) 1.73
Trends in heart disease deaths in Olmsted County, Minnesota, 1979-1994. Mayo Clin Proc (1999) 1.72
Use of echocardiography in the management of congestive heart failure in the community. J Am Coll Cardiol (1999) 1.69
Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology (1998) 1.68
p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem (2000) 1.64
Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy. J Urol (2000) 1.60
Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol (1999) 1.60
Is school vision screening effective? J Sch Health (1996) 1.59
Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res (1994) 1.59
Impact of arterial surgery and balloon angioplasty on amputation: a population-based study of 1155 procedures between 1973 and 1992. J Vasc Surg (1997) 1.58
Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology (1998) 1.57
PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res (2000) 1.57
Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis (2009) 1.54
Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol (1999) 1.53
Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: results of community based studies in 2 countries. J Urol (1996) 1.53
Epithelial noncarcinoid tumors and tumor-like lesions of the appendix. A clinicopathologic study of 184 patients with a multivariate analysis of prognostic factors. Cancer (1995) 1.53
The treatment of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol (1996) 1.49
Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol (1999) 1.48
Risk factors for perineal seeding of prostate cancer after needle biopsy. J Urol (1989) 1.47
Syncope in children and adolescents. J Am Coll Cardiol (1997) 1.45
The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc (1993) 1.45
Validation of death certificate diagnosis of out-of-hospital coronary heart disease deaths in Olmsted County, Minnesota. Mayo Clin Proc (2000) 1.45
p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol (1999) 1.44
Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol (1995) 1.44
Suppressed recombination and a pairing anomaly on the mating-type chromosome of Neurospora tetrasperma. Genetics (2000) 1.44
Pseudohomothallism and evolution of the mating-type chromosome in Neurospora tetrasperma. Genetics (1996) 1.41
Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J Gerontol A Biol Sci Med Sci (1995) 1.41
Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol (2000) 1.34
Vegetative incompatibility in the het-6 region of Neurospora crassa is mediated by two linked genes. Genetics (2000) 1.29
Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol (1996) 1.29
Chronology of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol (1996) 1.29
Prognostic value of treadmill exercise testing in elderly persons. Ann Intern Med (2000) 1.28
Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol (1999) 1.27
Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology (1997) 1.27
Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology (1996) 1.24
Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res (2001) 1.24
Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. J Urol (2000) 1.23
Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol (1997) 1.23
Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J Urol (2000) 1.22
Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene (2006) 1.21
A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics (2000) 1.20
Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol (1993) 1.19
Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology (2001) 1.19
Influence of patient age on the serum PSA concentration. An important clinical observation. Urol Clin North Am (1993) 1.19
Prognostic value of treadmill exercise testing: a population-based study in Olmsted County, Minnesota. Circulation (1999) 1.18